Shots:
- NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate
- PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns
- PostEra will also deploy its Manifold platform, providing access to compounds through a WW network of vendors and CROs
Click here to read full press release/ article | Ref: PRNewswire | Image: LinkedIn
The post PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease first appeared on PharmaShots.
